The advancements in the detection and characterization of circulating tumor DNA (ctDNA)
have revolutionized precision medicine and are likely to transform standard clinical practice …

Therapeutic management of NSCLC patients is quite challenging as they are mainly
diagnosed at a late stage of disease, and they present a high heterogeneous molecular …

Cell-free DNA (cfDNA) serves as a valuable biomarker for early disease detection and
monitoring. However, the use of cfDNA for analysis faces challenges owing to general low …

Emerging technologies focused on the detection and quantification of circulating tumor DNA
(ctDNA) in blood show extensive potential for managing patient treatment decisions …

Blood samples were collected from 18 healthy donors at the Aalborg University Hospital
Blood Bank (Aalborg, Denmark). Blood was drawn from each donor in four 9-mL EDTA …

Biomarker testing–based personalized medicine strategies can improve outcomes for
patients with cancer at the individual and population levels. 1, 2 The identification of …

In current clinical practice, effective cancer testing and screening paradigms are limited to
specific types of cancer, exhibiting varying efficiency, acceptance, and adherence. Cell-free …

Circulating cell-free DNA (cfDNA) refers to small fragments of DNA molecules released after
programmed cell death and necrosis in several body fluids such as blood, saliva, urine, and …

Clinical genomic testing of patient germline, tumor tissue, or plasma cell-free DNA can
enable a personalized approach to cancer management and treatment. In prostate cancer …

Introduction: PIK3CA gene mutations occur in approximately 40% of hormone receptor-
positive/HER2-negative (HR+/HER2−) metastatic breast cancers (MBCs), electing them to …